ClinicalTrials.gg
Not yet recruitingNCT07949890Updated Nov 19, 2026

Titrated Norepinephrine for Prophylaxis Against Intraoperative Hypotension in Emergency Surgery

An interventional study of Saline (0.9%, sterile, for infusion) and Norepinephrine in Emergency Surgery and Hypotension (MeSH: D007022), sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Cairo University · Not applicable, Interventional, and Prevention

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 33 studies in Hypotension by Cairo University — 10 open to participants now, 10 under way, 1 of them phase 3. Hypotension · Cairo University.

Planned enrollment
10th of 19
100 · median 100
Started
2026
with 5 others
No phase
14 of 33
7 open now
Registered
33rd of 33
by date

Among the 33 studies in Hypotension by Cairo University, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2026, is one of 14 with no phase, and was the 33rd registered.

Hypotension

893 studies on the registry are indexed under Hypotension; 197 are open to participants now.

Browse Hypotension studies →

Open to participants now

10 of the 33 studies in Hypotension by Cairo University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 112 Hypotension studies recruiting now, 51 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Hypotension by Cairo University, or all of them as a file.
02

Study summary

A titrated approach, initiating norepinephrine infusion only when non invasive mean arterial (MAP) falls below 75 mmHg, may provide more balanced hemodynamic control and reduce the risk of hypertension.

To the best of our knowledge, no studies have specifically evaluated prophylactic vasopressor use in patients undergoing emergency surgery for septic source control. In this study, we investigate the efficacy of titrated norepinephrine infusion as a prophylactic strategy against intraoperative hypotension in emergency surgery.

03

Conditions studied

  • Emergency Surgery
  • Hypotension (MeSH: D007022)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (>18 years), undergoing emergency surgery for elimination of septic focus

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac morbidities (impaired contractility with \< 40%, heart block, arrhythmias, tight valvular lesions)
  • Baseline MAP\<75 mmHg
  • > 35 Kg/m2,
  • Pregnant or lactating women,
  • Allergy of any of the study drugs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    control

    saline infusion

    Drug: Saline (0.9%, sterile, for infusion)

  • Active comparator
    prophylactic group

    norepinephrine infusion

    Drug: Norepinephrine

Interventions

  • DrugSaline (0.9%, sterile, for infusion)

    500 mL of normal saline will be used without the addition of any drug. The managing anesthetist will withdraw the solution into a 50 mL syringe. When intraoperative mean arterial pressure (MAP) decreases to less than MAP 75 mmHg, saline will be infused at a rate of 0.75 mL/kg/h

  • DrugNorepinephrine

    4000 mcg of norepinephrine will be diluted in 500 mL of normal saline to yield a final concentration of 8 mcg/mL. The managing anesthetist will withdraw the solution into a 50 mL syringe. When intraoperative mean arterial pressure (MAP) decreases to less than MAP 75 mmHg, the prepared norepinephrine will be infused at a rate of 0.75 mL/kg/h

06

What researchers measure

Primary outcomes

  1. incidence of intraoperative hypotension

    MAP \<65 mmHg or \< 70 % of baseline

    Time frame: immediately after induction of anesthesia until extubation

Secondary outcomes

  1. Area under a MAP of 65 mmHg

    Time frame: immediately after induction of anesthesia until extubation

  2. serum lactate

    Time frame: 30 minutes after extubation

  3. acute kidney injury

    Time frame: 24 hours after surgery

  4. delirium

    by Confusion Assessment Method (CAM) score

    Time frame: 24 hours after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

Of 212 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's planned 6 months is below that.

Counting every sponsor, half of 219 studies reached it within 12 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Dec 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949890
Lead sponsor
Cairo University
Responsible party
Ahmed Hasanin (Professor, Cairo University) — Principal investigator
First posted
Nov 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Maha M Mostafa, MD
Contact
maha.mostafa@cu.edu.eg
01000365115 ext. +2
maha m mostafa, md
Contact
maha.mostafa11@gmail.com
Ahmed Hasanin, MD
principal investigator · Cairo University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion